Article
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Molecular & cellular proteomics : MCP - 1 May 2017
Zhang Xu, Maity Tapan, Kashyap Manoj K, Bansal Mukesh, Venugopalan Abhilash, Singh Sahib, Awasthi Shivangi, Marimuthu Arivusudar, Charles Jacob Harrys Kishore, Belkina Natalya, Pitts Stephanie, Cultraro Constance M, Gao Shaojian, Kirkali Guldal, Biswas Romi, Chaerkady Raghothama, Califano Andrea, Pandey Akhilesh, Guha Udayan
Abstract excerpt
Mutations in the Epidermal growth factor receptor (EGFR) kinase domain, such as the L858R missense mutation and deletions spanning the conserved sequence 747LREA750, are sensitive to tyrosine kinase inhibitors (TKIs). The gatekeeper site residue mutation, T790M accounts for around 60% of acquired resistance to EGFR TKIs. The first generation EGFR TKIs, erlotinib and gefitinib, and the second generation inhibitor,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.